RNA, U6 small nuclear 644, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-644P profile across patient tissues and cancer cell-line models. RNU6-644P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU6-644P is differentially expressed in 4, with the highest sampling consensus in BLCA. Additionally, RNU6-644P RNA expression shows 6,811 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, BLCA, and KIRP as cancer lineages where RNU6-644P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-644P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-644P survival associations across molecular data types. RNU6-644P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-644P RNA expression–survival associations across cancer types. High RNU6-644P expression shows unfavorable associations in KIRC, LIHC, PCPG and CESC, but favorable associations in OV and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU6-644P RNA expression.
This table summarizes RNU6-644P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-644P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-644P shows lower tumor expression in BLCA, LUSC and KIRP and higher tumor expression in STAD. The BLCA box plot shows higher RNU6-644P RNA expression in normal versus tumor tissue (log2 FC = −0.218, t-test p = .015).
This table shows molecular features associated with RNU6-644P in patient tissues and cancer cell lines. In patient samples, RNU6-644P shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
